Upon his return to the United States Presidency, Donald Trump signed a number of executive orders that will not have an immediate impact, but will take effect in the coming weeks.

Trump rescinded Executive Order 14087, "Lowering Prescription Drug Costs for Americans," which directed Medicare and Medicaid agencies to research and implement models for lowering the costs of prescription drugs. Separate provisions in the Inflation Reduction Act of 2022 also aimed at lower prescription drug costs are still in effect.

President Donald Trump issued a flurry of executive orders and other actions on health care soon after reentering office. Other than signaling he intends to reverse many of Joe Biden’s moves, the orders will have little immediate impact.

Tripling the dosage of the Wegovy weight-loss drug leads to more weight loss, Novo Nordisk said Friday. The Danish drugmaker announced results from a Phase 3B trial of semaglutide at a 7.2 milligram dosage,

On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in Medicare.

President Donald Trump began his second administration with a blitz of policy actions to reorient U.S. government priorities.

The White House told federal agencies to detail by Friday a list of federal employees who are on probationary status and make recommendations on whether they should remain on the job.

Biden spent like no president in history, and, with a sleight of hand, by taking hundreds of billions out of Medicare and spending it on green energy subsidies.

Abe Sutton, a health policy aide in the first Trump administration, is likely to be named head of the Center for Medicare and Medicaid Innovation at CMS.

The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare Part-D for price negotiations, the next round of negotiations under the Inflation Reduction Act passed by President Joe Biden in 2022.

The White House on Friday said Novo Nordisk’s weight-loss drugs Wegovy and Ozempic were among the 15 medications picked for a round of price negotiations with Medicare. The companies do not have ...